Neelufar Mozaffarian

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg et al. · JAMA · 2019 · 305 citations · Full text

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet · 2018 · 251 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +7

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Bernard Combe, Alan Kivitz, Yoshiya Tanaka et al. · Annals of the Rheumatic Diseases · 2021 · 228 citations · Full text

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Philip J. Mease, Laura C. Coates, Philip Helliwell et al. · The Lancet · 2018 · 202 citations · Full text

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

René Westhovens, William F. C. Rigby, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2021 · 134 citations · Full text